News

NMD Pharma A/S, a CMTA-STAR Alliance Partner, recently announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD670, the investigational drug the company is studying in its ongoing Phase II SYNAPSE-CMT clinical trial. ...

The Simply CMT Podcast is presented by the Charcot-Marie-Tooth Association. This monthly podcast highlights the CMT community and the work of CMTA. Simply CMT. Empowering Patients, Accelerating Research. Simplified. Interested in being a guest? Email marketing@cmtausa.org View Archived CMT 4 Me Podcast ...

CMTA-STAR Alliance Partner NMD Pharma A/S has announced the publication of foundational findings in the Annals of Clinical and Translational Neurology. The study highlights neuromuscular junction (NMJ) dysfunction as a characteristic in Charcot-Marie-Tooth disease (CMT) types 1 and 2, identifying ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is proud to announce the designation of a new CMTA Center of ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is thrilled to announce the designation of a new CMTA Center of ...